nach oben

Cancer and Metastasis Reviews

Erschienen in:

16.11.2019 | Metastasis

The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding

verfasst von: Marta Helena Kubala, Yves Albert DeClerck

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 3/2019

Einloggen, um Zugang zu erhalten

Abstract

The paradoxical pro-tumorigenic function of plasminogen activator inhibitor 1 (PAI-1, aka Serpin E1) in cancer progression and metastasis has been the subject of an abundant scientific literature that has pointed to a pro-angiogenic role, a growth and migration stimulatory function, and an anti-apoptotic activity, all directed toward promoting tumor growth, cancer cell survival, and metastasis. With uPA, PAI-1 is among the most reliable biomarkers and prognosticators in many cancer types. More recently, a novel pro-tumorigenic function of PAI-1 in cancer-related inflammation has been demonstrated. These multifaceted activities of PAI-1 in cancer progression are explained by the complex structure of PAI-1 and its multiple functions that go beyond its anti-fibrinolytic and anti-plasminogen activation activities. However, despite the multiple evidences supporting a pro-tumorigenic role of PAI-1 in cancer, and the development of several inhibitors, targeting PAI-1, has remained elusive. In this article, the various mechanisms responsible for the pro-tumorigenic functions of PAI-1 are reviewed with emphasis on its more recently described contribution to cancer inflammation. The challenges of targeting PAI-1 in cancer therapy are then discussed.

Unkeless, J. C., Tobia, A., Ossowski, L., Quigley, J. P., Rifkin, D. B., & Reich, E. (1973). Enzymatic function associated with transformation of fibroblasts by oncogenic viruses. 1. Chick-embryo fibroblast cultures transformed by avian rna tumor-viruses. Journal of Experimental Medicine, 137(1), 85–111.

Duffy, M. J., Reilly, D., McDermott, E., O'Higgins, N., Fennelly, J. J., & Andreasen, P. A. (1994). Urokinase plasminogen activator as a prognostic marker in different subgroups of patients with breast cancer. Cancer, 74(8), 2276–2280. https://doi.org/10.1002/1097-0142(19941015)74:8<2276::aid-cncr2820740811>3.0.co;2-7.CrossRefPubMed

Duggan, C., Maguire, T., McDermott, E., OHiggins, N., Fennelly, J. J., & Duffy, M. J. (1995). Urokinase plasminogen activator and urokinase plasminogen activator receptor in breast cancer. Int.J.Cancer, 61, 597–600.PubMedCrossRef

Grondahl-Hansen, J., Peters, H. A., van Putten, W. L., Look, M. P., Pappot, H., Ronne, E., et al. (1995). Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clinical Cancer Research, 1(10), 1079–1087.PubMed

Annecke, K., Schmitt, M., Euler, U., Zerm, M., Paepke, D., Paepke, S., et al. (2008). uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial. Advances in Clinical Chemistry, 45(45), 31–45.PubMedCrossRef

Janicke, F., Prechtl, A., Thomssen, C., Harbeck, N., Meisner, C., Untch, M., Sweep, C. G. J. F., Selbmann, H. K., Graeff, H., & Schmitt, M. (2001). Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. Journal of the National Cancer Institute, 93(12), 913–920.PubMedCrossRef

Binder, B. R., & Mihaly, J. (2008). The plasminogen activator inhibitor “paradox” in cancer. Immunology Letters, 118(2), 116–124.PubMedCrossRef

Schmitt, M., Harbeck, N., Brunner, N., Janicke, F., Meisner, C., Muhlenweg, B., et al. (2011). Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1. Expert Review of Molecular Diagnostics, 11(6), 617–634.PubMedCrossRef

Kwaan, H. C., Mazar, A. P., & McMahon, B. J. (2013). The apparent uPA/PAI-1 paradox in cancer: more than meets the eye. Seminars in Thrombosis and Hemostasis, 39(4), 382–391. https://doi.org/10.1055/s-0033-1338127.CrossRefPubMed

10.

Foekens, J. A., Schmitt, M., van Putten, W. L., Peters, H. A., Kramer, M. D., Janicke, F., et al. (1994). Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J.Clin.Oncol., 12, 1648–1658.PubMedCrossRef

11.

Foekens, J. A., Look, M. P., Peters, H. A., van Putten, W. L., Portengen, H., & Klijn, J. G. (1995). Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J.Natl.Cancer Inst., 87(10), 751–756.PubMedCrossRef

12.

Wind, T., Hansen, M., Jensen, J. K., & Andreasen, P. A. (2002). The molecular basis for anti-proteolytic and non-proteolytic functions of plasminogen activator inhibitor type-1: roles of the reactive centre loop, the shutter region, the flexible joint region and the small serpin fragment. Biol.Chem, 383(1), 21–36. https://doi.org/10.1515/BC.2002.003.CrossRefPubMed

13.

Mottonen, J., Strand, A., Symersky, J., Sweet, R. M., Danley, D. E., Geoghegan, K. F., Gerard, R. D., & Goldsmith, E. J. (1992). Structural basis of latency in plasminogen activator inhibitor-1. Nature, 355(6357), 270–273. https://doi.org/10.1038/355270a0.CrossRefPubMed

14.

Seiffert, D., & Loskutoff, D. J. (1991). Evidence that type 1 plasminogen activator inhibitor binds to the somatomedin B domain of vitronectin. The Journal of Biological Chemistry, 266(5), 2824–2830.PubMed

15.

Lawrence, D. A., Berkenpas, M. B., Palaniappan, S., & Ginsburg, D. (1994). Localization of vitronectin binding domain in plasminogen activator inhibitor-1. J.Biol.Chem., 269(21), 15223–15228.PubMed

16.

Mimuro, J., & Loskutoff, D. J. (1989). Purification of a protein from bovine plasma that binds to type 1 plasminogen activator inhibitor and prevents its interaction with extracellular matrix. Evidence that the protein is vitronectin. The Journal of Biological Chemistry, 264(2), 936–939.PubMed

17.

Madsen, C. D., Ferraris, G. M., Andolfo, A., Cunningham, O., & Sidenius, N. (2007). uPAR-induced cell adhesion and migration: vitronectin provides the key. The Journal of Cell Biology, 177(5), 927–939. https://doi.org/10.1083/jcb.200612058.CrossRefPubMedPubMedCentral

18.

Jensen, J. K., Malmendal, A., Schiott, B., Skeldal, S., Pedersen, K. E., Celik, L., et al. (2006). Inhibition of plasminogen activator inhibitor-1 binding to endocytosis receptors of the low-density-lipoprotein receptor family by a peptide isolated from a phage display library. The Biochemical Journal, 399(3), 387–396. https://doi.org/10.1042/bj20060533.CrossRefPubMedPubMedCentral

19.

Webb, D. J., Nguyen, D. H., Sankovic, M., & Gonias, S. L. (1999). The very low density lipoprotein receptor regulates urokinase receptor catabolism and breast cancer cell motility in vitro. The Journal of Biological Chemistry, 274(11), 7412–7420. https://doi.org/10.1074/jbc.274.11.7412.CrossRefPubMed

20.

Placencio, V. R., & DeClerck, Y. A. (2015). Plasminogen activator inhibitor-1 in cancer: rationale and insight for future therapeutic testing. Cancer Research, 75(15), 2969–2974. https://doi.org/10.1158/0008-5472.can-15-0876.CrossRefPubMedPubMedCentral

21.

Look, M. P., van Putten, W. L., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., et al. (2002). Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl.Cancer Inst., 94(2), 116–128.PubMedCrossRef

22.

Knoop, A., Andreasen, P. A., Andersen, J. A., Hansen, S., Lænkholm, A. V., Simonsen, A. C. W., Andersen, J., Overgaard, J., & Rose, C. (1998). Prognostic significance of urokinase-type plasminogen activator and plasminogen activator inhibitor-1 in primary breast cancer. Br.J.Cancer, 77(6), 932–940.PubMedPubMedCentralCrossRef

23.

Niki, M., Yokoi, T., Kurata, T., & Nomura, S. (2017). New prognostic biomarkers and therapeutic effect of bevacizumab for patients with non-small-cell lung cancer. Lung Cancer (Auckl), 8, 91–99. https://doi.org/10.2147/lctt.s138887.CrossRef

24.

Harbeck, N., Schmitt, M., Meisner, C., Friedel, C., Untch, M., Schmidt, M., Sweep, C. G. J., Lisboa, B. W., Lux, M. P., Beck, T., Hasmüller, S., Kiechle, M., Jänicke, F., & Thomssen, C. (2013). Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients. European Journal of Cancer, 49(8), 1825–1835. https://doi.org/10.1016/j.ejca.2013.01.007.CrossRefPubMed

25.

Mazzoccoli, G., Pazienza, V., Panza, A., Valvano, M. R., Benegiamo, G., Vinciguerra, M., Andriulli, A., & Piepoli, A. (2012). ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer. Journal of Cancer Research and Clinical Oncology, 138(3), 501–511. https://doi.org/10.1007/s00432-011-1126-6.CrossRefPubMed

26.

Robert, C., Bolon, I., Gazzeri, S., Veyrenc, S., Brambilla, C., & Brambilla, E. (1999). Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression. Clin.Cancer Res., 5(8), 2094–2102.PubMed

27.

Fujii, T., Obara, T., Tanno, S., Ura, H., & Kohgo, Y. (1999). Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas. Hepatogastroenterology, 46(28), 2299–2308.PubMed

28.

Chambers, S. K., Ivins, C. M., & Carcangiu, M. L. (1998). Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int.J.Cancer, 79(5), 449–454.PubMedCrossRef

29.

Dossenbach-Glaninger, A., van Trotsenburg, M., Dossenbach, M., Oberkanins, C., Moritz, A., Krugluger, W., et al. (2003). Plasminogen activator inhibitor 1 4G/5G polymorphism and coagulation factor XIII Val34Leu polymorphism: impaired fibrinolysis and early pregnancy loss. Clinical Chemistry, 49(7), 1081–1086.PubMedCrossRef

30.

Yildirim, M. E., Karakus, S., Kurtulgan, H. K., Kilicgun, H., Ersan, S., & Bakir, S. (2017). The Association of Plasminogen Activator Inhibitor Type 1 (PAI-1) level and PAI-1 4G/5G gene polymorphism with the formation and the grade of endometrial cancer. Biochemical Genetics, 55(4), 314–321. https://doi.org/10.1007/s10528-017-9796-7.CrossRefPubMed

31.

Castello, R., Espana, F., Vazquez, C., Fuster, C., Almenar, S. M., Aznar, J., et al. (2006). Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity. Thrombosis Research, 117(5), 487–492. https://doi.org/10.1016/j.thromres.2005.03.025.CrossRefPubMed

32.

Jevric, M., Matic, I. Z., Krivokuca, A., Dordic Crnogorac, M., Besu, I., Damjanovic, A., et al. (2019). Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy. BMC Cancer, 19(1), 71. https://doi.org/10.1186/s12885-018-5255-z.CrossRefPubMedPubMedCentral

33.

Divella, R., Daniele, A., Abbate, I., Savino, E., Casamassima, P., Sciortino, G., Simone, G., Gadaleta-Caldarola, G., Fazio, V., Gadaleta, C. D., Sabbà, C., & Mazzocca, A. (2015). Circulating levels of PAI-1 and SERPINE1 4G/4G polymorphism are predictive of poor prognosis in HCC patients undergoing TACE. Translational Oncology, 8(4), 273–278. https://doi.org/10.1016/j.tranon.2015.05.002.CrossRefPubMedPubMedCentral

34.

Gilabert-Estelles, J., Ramon, L. A., Braza-Boils, A., Gilabert, J., Chirivella, M., Espana, F., et al. (2012). Plasminogen activator inhibitor-1 (PAI-1) 4 G/5 G polymorphism and endometrial cancer. Influence of PAI-1 polymorphism on tissue PAI-1 antigen and mRNA expression and tumor severity. Thrombosis Research, 130(2), 242–247. https://doi.org/10.1016/j.thromres.2011.10.007.CrossRefPubMed

35.

Vairaktaris, E., Yapijakis, C., Serefoglou, Z., Vylliotis, A., Ries, J., Nkenke, E., Wiltfang, J., Derka, S., Vassiliou, S., Springer, I., Kessler, P., & Neukam, F. W. (2006). Plasminogen activator inhibitor-1 polymorphism is associated with increased risk for oral cancer. Oral Oncology, 42(9), 888–892. https://doi.org/10.1016/j.oraloncology.2005.12.005.CrossRefPubMed

36.

Forsti, A., Lei, H., Tavelin, B., Enquist, K., Palmqvist, R., Altieri, A., Hallmans, G., Hemminki, K., & Lenner, P. (2007). Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer. Annals of Oncology, 18(12), 1990–1994. https://doi.org/10.1093/annonc/mdm361.CrossRefPubMed

37.

Sternlicht, M. D., Dunning, A. M., Moore, D. H., Pharoah, P. D., Ginzinger, D. G., Chin, K., et al. (2006). Prognostic value of PAI1 in invasive breast cancer: evidence that tumor-specific factors are more important than genetic variation in regulating PAI1 expression. Cancer Epidemiology, Biomarkers & Prevention, 15(11), 2107–2114. https://doi.org/10.1158/1055-9965.epi-06-0351.CrossRef

38.

Li, H., Shinohara, E. T., Cai, Q., Chen, H., Courtney, R., Cao, C., Wang, Z., Teng, M., Zheng, W., & Lu, B. (2006). Plasminogen activator inhibitor-1 promoter polymorphism is not associated with the aggressiveness of disease in prostate cancer. Clinical Oncology (Royal College of Radiologists), 18(4), 333–337.CrossRef

39.

Loktionov, A., Watson, M. A., Stebbings, W. S., Speakman, C. T., & Bingham, S. A. (2003). Plasminogen activator inhibitor-1 gene polymorphism and colorectal cancer risk and prognosis. Cancer Letters, 189(2), 189–196.PubMedCrossRef

40.

Blasiak, J., & Smolarz, B. (2000). Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer. Acta Biochimica Polonica, 47(1), 191–199.PubMed

41.

Lee, J. H., Kim, Y., Choi, J. W., & Kim, Y. S. (2013). Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis. Archives of Medical Research, 44(1), 39–45. https://doi.org/10.1016/j.arcmed.2012.12.002.CrossRefPubMed

42.

Baker, S., Ali, I., Silins, I., Pyysalo, S., Guo, Y., Hogberg, J., et al. (2017). Cancer hallmarks analytics tool (CHAT): a text mining approach to organize and evaluate scientific literature on cancer. Bioinformatics, 33(24), 3973–3981. https://doi.org/10.1093/bioinformatics/btx454.CrossRefPubMedPubMedCentral

43.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell, 144(5), 646–674.PubMedCrossRef

44.

Giacoia, E. G., Miyake, M., Lawton, A., Goodison, S., & Rosser, C. J. (2014). PAI-1 leads to G1-phase cell-cycle progression through cyclin D3/cdk4/6 upregulation. Molecular Cancer Research, 12(3), 322–334. https://doi.org/10.1158/1541-7786.mcr-13-0543.CrossRefPubMed

45.

Vial, D., Monaghan-Benson, E., & McKeown-Longo, P. J. (2006). Coordinate regulation of fibronectin matrix assembly by the plasminogen activator system and vitronectin in human osteosarcoma cells. Cancer Cell International, 6, 8. https://doi.org/10.1186/1475-2867-6-8.CrossRefPubMedPubMedCentral

46.

Kortlever, R. M., & Bernards, R. (2006). Senescence, wound healing and cancer: the PAI-1 connection. Cell Cycle, 5(23), 2697–2703.PubMedCrossRef

47.

Aguirre-Ghiso, J. A., Estrada, Y., Liu, D., & Ossowski, L. (2003). ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK). Cancer Research, 63(7), 1684–1695.PubMed

48.

McEachron, T. A., Church, F. C., & Mackman, N. (2011). Regulation of thrombin-induced plasminogen activator inhibitor-1 in 4T1 murine breast cancer cells. Blood Coagulation & Fibrinolysis, 22(7), 576–582. https://doi.org/10.1097/MBC.0b013e3283497647.CrossRef

49.

McEachron, T. A., Pawlinski, R., Richards, K. L., Church, F. C., & Mackman, N. (2010). Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis. Blood, 116(23), 5037–5044. https://doi.org/10.1182/blood-2010-06-293126.CrossRefPubMedPubMedCentral

50.

Mazzieri, R., & Blasi, F. (2005). The urokinase receptor and the regulation of cell proliferation. Thrombosis and Haemostasis, 93(4), 641–646. https://doi.org/10.1160/th05-01-0021.CrossRefPubMed

51.

Lademann, U. A., & Romer, M. U. (2008). Regulation of programmed cell death by plasminogen activator inhibitor type 1 (PAI-1). Thrombosis and Haemostasis, 100(6), 1041–1046.PubMed

52.

Balsara, R. D., & Ploplis, V. A. (2008). Plasminogen activator inhibitor-1: the double-edged sword in apoptosis. Thrombosis and Haemostasis, 100(6), 1029–1036.PubMedPubMedCentralCrossRef

53.

Fang, H., Placencio, V. R., & DeClerck, Y. A. (2012). Protumorigenic activity of plasminogen activator inhibitor-1 through an antiapoptotic function. J Natl Cancer Inst, 104(19), 1470–1484. https://doi.org/10.1093/jnci/djs377.CrossRefPubMedPubMedCentral

54.

Valiente, M., Obenauf, A. C., Jin, X., Chen, Q., Zhang, X. H., Lee, D. J., et al. (2014). Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell, 156(5), 1002–1016. https://doi.org/10.1016/j.cell.2014.01.040.CrossRefPubMedPubMedCentral

55.

Bajou, K., Peng, H., Laug, W. E., Maillard, C., Noel, A., Foidart, J. M., et al. (2008). Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell, 14(4), 324–334.PubMedPubMedCentralCrossRef

56.

Isogai, C., Laug, W. E., Shimada, H., Declerck, P. J., Stins, M. F., Durden, D. L., Erdreich-Epstein, A., & DeClerck, Y. (2001). Plasminogen activator inhibitor-1 promotes angiogenesis by stimulating endothelial cell migration toward fibronectin. Cancer Research, 61(14), 5587–5594.PubMed

57.

Olander, J. V., Bremer, M. E., Marasa, J. C., & Feder, J. (1985). Fibrin-enhanced endothelial cell organization. Journal of Cellular Physiology, 125(1), 1–9. https://doi.org/10.1002/jcp.1041250102.CrossRefPubMed

58.

Qi, J., Goralnick, S., & Kreutzer, D. L. (1997). Fibrin regulation of interleukin-8 gene expression in human vascular endothelial cells. Blood, 90(9), 3595–3602.PubMedCrossRef

59.

Liu, G., Shuman, M. A., & Cohen, R. L. (1995). Co-expression of urokinase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cancer cells. International Journal of Cancer, 60(4), 501–506.PubMedCrossRef

60.

Maillard, C. M., Bouquet, C., Petitjean, M. M., Mestdagt, M., Frau, E., Jost, M., Masset, A. M., Opolon, P. H., Beermann, F., Abitbol, M. M., Foidart, J. M., Perricaudet, M. J., & Noel, A. C. (2008). Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors. Carcinogenesis, 29(11), 2236–2242. https://doi.org/10.1093/carcin/bgn204.CrossRefPubMed

61.

Zhang, W., Xu, J., Fang, H., Tang, L., Chen, W., Sun, Q., Zhang, Q., Yang, F., Sun, Z., Cao, L., Wang, Y., & Guan, X. (2018). Endothelial cells promote triple-negative breast cancer cell metastasis via PAI-1 and CCL5 signaling. The FASEB Journal, 32(1), 276–288. https://doi.org/10.1096/fj.201700237RR.CrossRefPubMed

62.

Tsuchiya, H., Katsuo, S., Matsuda, E., Sunayama, C., Tomita, K., Ueda, Y., et al. (1995). The antibody to plasminogen activator inhibitor-1 suppresses pulmonary metastases of human fibrosarcoma in athymic mice. General & Diagnostic Pathology, 141(1), 41–48.

63.

Tsuchiya, H., Sunayama, C., Okada, G., Matsuda, E., Tomita, K., & Binder, B. R. (1997). Plasminogen activator inhibitor-1 accelerates lung metastasis formation of human fibrosarcoma cells. Anticancer Research, 17(1A), 313–316.PubMed

64.

Chen, H., Peng, H., Liu, W., Sun, Y., Su, N., Tang, W., Zhang, X., Wang, J., Cui, L., Hu, P., & Liu, S. (2015). Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis. Surgery, 158(6), 1704–1713. https://doi.org/10.1016/j.surg.2015.04.053.CrossRefPubMed

65.

Nishioka, N., Matsuoka, T., Yashiro, M., Hirakawa, K., Olden, K., & Roberts, J. D. (2012). Plasminogen activator inhibitor 1 RNAi suppresses gastric cancer metastasis in vivo. Cancer Science, 103(2), 228–232. https://doi.org/10.1111/j.1349-7006.2011.02155.x.CrossRefPubMedPubMedCentral

66.

Alizadeh, H., Ma, D., Berman, M., Bellingham, D., Comerford, S. A., Gething, M. J., et al. (1995). Tissue-type plasminogen activator-induced invasion and metastasis of murine melanomas. Current Eye Research, 14(6), 449–458.PubMedCrossRef

67.

Masuda, T., Hattori, N., Senoo, T., Akita, S., Ishikawa, N., Fujitaka, K., Haruta, Y., Murai, H., & Kohno, N. (2013). SK-216, an inhibitor of plasminogen activator inhibitor-1, limits tumor progression and angiogenesis. Molecular Cancer Therapeutics, 12(11), 2378–2388. https://doi.org/10.1158/1535-7163.mct-13-0041.CrossRefPubMed

68.

Soff, G. A., Sanderowitz, J., Gately, S., Verrusio, E., Weiss, I., Brem, S., & Kwaan, H. C. (1995). Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor- associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J.Clin.Invest., 96(6), 2593–2600.PubMedPubMedCentralCrossRef

69.

Inoue, M., Sawada, T., Uchima, Y., Kimura, K., Nishihara, T., Tanaka, H., Yashiro, M., Yamada, N., Ohira, M., & Hirakawa, K. (2005). Plasminogen activator inhibitor-1 (PAI-1) gene transfection inhibits the liver metastasis of pancreatic cancer by preventing angiogenesis. Oncology Reports, 14(6), 1445–1451.PubMed

70.

Ma, D., Gerard, R. D., Li, X. Y., Alizadeh, H., & Niederkorn, J. Y. (1997). Inhibition of metastasis of intraocular melanomas by adenovirus- mediated gene transfer of plasminogen activator inhibitor type I (PAI-1) in an athymic mouse model. Blood, 90(7), 2738–2746.PubMedCrossRef

71.

Park, J., Wysocki, R. W., Amoozgar, Z., Maiorino, L., Fein, M. R., Jorns, J., et al. (2016). Cancer cells induce metastasis-supporting neutrophil extracellular DNA traps. Sci Transl Med, 8(361), 361ra138. https://doi.org/10.1126/scitranslmed.aag1711.CrossRefPubMedPubMedCentral

72.

Noubouossie, D. F., Reeves, B. N., Strahl, B. D., & Key, N. S. (2019). Neutrophils: back in the thrombosis spotlight. Blood, 133(20), 2186–2197. https://doi.org/10.1182/blood-2018-10-862243.CrossRefPubMedPubMedCentral

73.

Oda, T., Jung, Y. O., Kim, H. S., Cai, X., Lopez-Guisa, J. M., Ikeda, Y., et al. (2001). PAI-1 deficiency attenuates the fibrogenic response to ureteral obstruction. Kidney International, 60(2), 587–596. https://doi.org/10.1046/j.1523-1755.2001.030002587.x.CrossRefPubMed

74.

Gupta, K. K., Xu, Z., Castellino, F. J., & Ploplis, V. A. (2016). Plasminogen activator inhibitor-1 stimulates macrophage activation through Toll-like Receptor-4. Biochemical and Biophysical Research Communications, 477(3), 503–508. https://doi.org/10.1016/j.bbrc.2016.06.065.CrossRefPubMed

75.

Ichimura, A., Matsumoto, S., Suzuki, S., Dan, T., Yamaki, S., Sato, Y., Kiyomoto, H., Ishii, N., Okada, K., Matsuo, O., Hou, F. F., Vaughan, D. E., van Ypersele de Strihou, C., & Miyata, T. (2013). A small molecule inhibitor to plasminogen activator inhibitor 1 inhibits macrophage migration. Arteriosclerosis, Thrombosis, and Vascular Biology, 33(5), 935–942. https://doi.org/10.1161/atvbaha.113.301224.CrossRefPubMed

76.

Kubala, M. H., Punj, V., Placencio-Hickok, V. R., Fang, H., Fernandez, G. E., Sposto, R., et al. (2018). Plasminogen activator inhibitor-1 promotes the recruitment and polarization of macrophages in cancer. Cell Rep, 25(8), 2177–2191.e2177. https://doi.org/10.1016/j.celrep.2018.10.082.CrossRefPubMedPubMedCentral

77.

Beaulieu, L. M., Whitley, B. R., Wiesner, I. T. F., Rehault, S. M., Palmieri, D., Elkahloun, A. G., et al. (2007). Breast cancer and metabolic syndrome linked through the plasminogen activator inhibitor-1 cycle. Bioessays, 29(10), 1029–1038.PubMedPubMedCentralCrossRef

78.

Schneider, D. J., Chen, Y., & Sobel, B. E. (2008). The effect of plasminogen activator inhibitor type 1 on apoptosis. Thrombosis and Haemostasis, 100(6), 1037–1040.PubMed

79.

Bajou, K., Masson, V., Gerard, R. D., Schmitt, P. M., Albert, V., Praus, M., Lund, L. R., Frandsen, T. L., Brunner, N., Dano, K., Fusenig, N. E., Weidle, U., Carmeliet, G., Loskutoff, D., Collen, D., Carmeliet, P., Foidart, J. M., & Noël, A. (2001). The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. The Journal of Cell Biology, 152(4), 777–784.PubMedPubMedCentralCrossRef

80.

Brooks, T. D., Slomp, J., Quax, P. H., De Bart, A. C., Spencer, M. T., Verheijen, J. H., et al. (2000). Antibodies to PAI-1 alter the invasive and migratory properties of human tumour cells in vitro. Clinical & Experimental Metastasis, 18(6), 445–453.CrossRef

81.

Eitzman, D. T., Krauss, J. C., Shen, T., Cui, J., & Ginsburg. (1996). Lack of plasminogen activator inhibitor-1 effect in a transgenic mouse model of metastatic melanoma. Blood., 87(11), 4718–4722.PubMed

82.

Almholt, K., Nielsen, B. S., Frandsen, T. L., Brunner, N., Dano, K., & Johnsen, M. (2003). Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene, 22(28), 4389–4397.PubMedCrossRef

83.

Bajou, K., Maillard, C., Jost, M., Lijnen, R. H., Gils, A., Declerck, P., Carmeliet, P., Foidart, J. M., & Noel, A. (2004). Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene, 23(41), 6986–6990.PubMedCrossRef

84.

Declerck, P. J., Gils, A., & De Taeye, B. (2011). Use of mouse models to study plasminogen activator inhibitor-1. Methods in Enzymology, 499, 77–104.PubMedCrossRef

85.

Levi, M., & van der Poll, T. (2017). Coagulation and sepsis. Thrombosis Research, 149, 38–44. https://doi.org/10.1016/j.thromres.2016.11.007.CrossRefPubMed

86.

Srikanthan, K., Feyh, A., Visweshwar, H., Shapiro, J. I., & Sodhi, K. (2016). Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the west Virginian population. International Journal of Medical Sciences, 13(1), 25–38. https://doi.org/10.7150/ijms.13800.CrossRefPubMedPubMedCentral

87.

Russolillo, A., Iervolino, S., Peluso, R., Lupoli, R., Di Minno, A., Pappone, N., et al. (2013). Obesity and psoriatic arthritis: from pathogenesis to clinical outcome and management. Rheumatology (Oxford), 52(1), 62–67. https://doi.org/10.1093/rheumatology/kes242.CrossRef

88.

Mertens, I., Verrijken, A., Michiels, J. J., Van der Planken, M., Ruige, J. B., & Van Gaal, L. F. (2006). Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. International Journal of Obesity, 30(8), 1308–1314. https://doi.org/10.1038/sj.ijo.0803189.CrossRefPubMed

89.

Franceschi, C., Bonafe, M., Valensin, S., Olivieri, F., De Luca, M., Ottaviani, E., et al. (2000). Inflamm-aging. An evolutionary perspective on immunosenescence. Annals of the New York Academy of Sciences, 908, 244–254. https://doi.org/10.1111/j.1749-6632.2000.tb06651.x.CrossRefPubMed

90.

Kruithof, E. K., Mestries, J. C., Gascon, M. P., & Ythier, A. (1997). The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6. Thrombosis and Haemostasis, 77(5), 905–910.PubMedCrossRef

91.

Sawdey, M. S., & Loskutoff, D. J. (1991). Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. The Journal of Clinical Investigation, 88(4), 1346–1353. https://doi.org/10.1172/jci115440.CrossRefPubMedPubMedCentral

92.

Varki, A. (2007). Trousseau’s syndrome: multiple definitions and multiple mechanisms. Blood, 110(6), 1723–1729. https://doi.org/10.1182/blood-2006-10-053736.CrossRefPubMedPubMedCentral

93.

Xu, X., Wang, H., Wang, Z., & Xiao, W. (2009). Plasminogen activator inhibitor-1 promotes inflammatory process induced by cigarette smoke extraction or lipopolysaccharides in alveolar epithelial cells. Experimental Lung Research, 35(9), 795–805. https://doi.org/10.3109/01902140902912519.CrossRefPubMed

94.

Ashton-Rickardt, P. G. (2013). An emerging role for serine protease inhibitors in T lymphocyte immunity and beyond. Immunology Letters, 152(1), 65–76. https://doi.org/10.1016/j.imlet.2013.04.004.CrossRefPubMed

95.

Rouch, A., Vanucci-Bacque, C., Bedos-Belval, F., & Baltas, M. (2015). Small molecules inhibitors of plasminogen activator inhibitor-1 - an overview. European Journal of Medicinal Chemistry, 92, 619–636. https://doi.org/10.1016/j.ejmech.2015.01.010.CrossRefPubMed

96.

Mutoh, M., Niho, N., Komiya, M., Takahashi, M., Ohtsubo, R., Nakatogawa, K., Ueda, K., Sugimura, T., & Wakabayashi, K. (2008). Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in min mice. Carcinogenesis, 29(4), 824–829. https://doi.org/10.1093/carcin/bgn028.CrossRefPubMed

97.

Takayama, Y., Hattori, N., Hamada, H., Masuda, T., Omori, K., Akita, S., Iwamoto, H., Fujitaka, K., & Kohno, N. (2016). Inhibition of PAI-1 limits tumor angiogenesis regardless of angiogenic stimuli in malignant pleural mesothelioma. Cancer Research, 76(11), 3285–3294. https://doi.org/10.1158/0008-5472.can-15-1796.CrossRefPubMed

98.

Gomes-Giacoia, E., Miyake, M., Goodison, S., & Rosser, C. J. (2013). Targeting plasminogen activator inhibitor-1 inhibits angiogenesis and tumor growth in a human cancer xenograft model. Molecular Cancer Therapeutics, 12(12), 2697–2708. https://doi.org/10.1158/1535-7163.mct-13-0500.CrossRefPubMedPubMedCentral

99.

Placencio, V. R., Ichimura, A., Miyata, T., & DeClerck, Y. A. (2015). Small molecule inhibitors of plasminogen activator inhibitor-1 elicit anti-tumorigenic and anti-angiogenic activity. PLoS One, 10(7), e0133786. https://doi.org/10.1371/journal.pone.0133786.CrossRefPubMedPubMedCentral

100.

Mashiko, S., Kitatani, K., Toyoshima, M., Ichimura, A., Dan, T., Usui, T., Ishibashi, M., Shigeta, S., Nagase, S., Miyata, T., & Yaegashi, N. (2015). Inhibition of plasminogen activator inhibitor-1 is a potential therapeutic strategy in ovarian cancer. Cancer Biology & Therapy, 16(2), 253–260. https://doi.org/10.1080/15384047.2014.1001271.CrossRef

101.

Gorlatova, N. V., Cale, J. M., Elokdah, H., Li, D., Fan, K., Warnock, M., Crandall, D. L., & Lawrence, D. A. (2007). Mechanism of inactivation of plasminogen activator inhibitor-1 by a small molecule inhibitor. The Journal of Biological Chemistry, 282(12), 9288–9296. https://doi.org/10.1074/jbc.M611642200.CrossRefPubMed

102.

Wun, T. C., & Kretzmer, K. K. (1987). cDNA cloning and expression in E. coli of a plasminogen activator inhibitor (PAI) related to a PAI produced by Hep G2 hepatoma cell. FEBS Letters, 210(1), 11–16. https://doi.org/10.1016/0014-5793(87)81288-7.CrossRefPubMed

103.

Busso, N., Belin, D., Failly-Crepin, C., & Vassalli, J. D. (1987). Glucocorticoid modulation of plasminogen activators and of one of their inhibitors in the human mammary carcinoma cell line MDA-MB-231. Cancer Research, 47(2), 364–370.PubMed

Titel: The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding
verfasst von: Marta Helena Kubala
Yves Albert DeClerck
Publikationsdatum: 16.11.2019
Verlag: Springer US
Schlagwörter: Metastasis
Fibrinolytic Therapy
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 3/2019
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-019-09806-4

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

The plasminogen activator inhibitor-1 paradox in cancer: a mechanistic understanding

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2019

Current management of succinate dehydrogenase–deficient gastrointestinal stromal tumors

KISS1 in breast Cancer progression and autophagy

Biography—Judith Clements

Specifically targeting cancer proliferation and metastasis processes: the development of matriptase inhibitors

Preface to “Proteases in Cancer Progression and Metastasis” special issue

Functional disparities within the TIMP family in cancer: hints from molecular divergence

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie